Variety of eligible individuals: CDEC mentioned the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some sufferers who are labeled as having mild or moderate illness may have a severe bleeding phenotype, https://hemgenix20637.wizzardsblog.com/35994810/everything-about-hemgenix